Healthcare of Ontario Pension Plan Trust Fund raised its holdings in AstraZeneca PLC (NASDAQ:AZN - Free Report) by 110.0% in the 3rd quarter, according to its most recent 13F filing with the SEC. The fund owned 112,569 shares of the company's stock after acquiring an additional 58,970 shares during the period. Healthcare of Ontario Pension Plan Trust Fund's holdings in AstraZeneca were worth $8,770,000 at the end of the most recent reporting period.
Other large investors also recently made changes to their positions in the company. McClarren Financial Advisors Inc. lifted its holdings in shares of AstraZeneca by 320.8% during the 3rd quarter. McClarren Financial Advisors Inc. now owns 324 shares of the company's stock worth $25,000 after acquiring an additional 247 shares during the period. GHP Investment Advisors Inc. purchased a new position in AstraZeneca during the second quarter worth approximately $26,000. Capital Performance Advisors LLP acquired a new position in shares of AstraZeneca in the 3rd quarter valued at $28,000. Pathway Financial Advisers LLC purchased a new stake in shares of AstraZeneca during the 1st quarter valued at $29,000. Finally, CANADA LIFE ASSURANCE Co increased its holdings in shares of AstraZeneca by 40.6% during the 1st quarter. CANADA LIFE ASSURANCE Co now owns 506 shares of the company's stock worth $34,000 after buying an additional 146 shares during the last quarter. Hedge funds and other institutional investors own 20.35% of the company's stock.
Wall Street Analysts Forecast Growth
A number of equities research analysts have issued reports on AZN shares. UBS Group raised AstraZeneca from a "sell" rating to a "neutral" rating in a research report on Wednesday, November 20th. Erste Group Bank raised shares of AstraZeneca from a "hold" rating to a "buy" rating in a research report on Wednesday, September 11th. Deutsche Bank Aktiengesellschaft upgraded shares of AstraZeneca from a "sell" rating to a "hold" rating in a report on Wednesday, November 6th. Finally, TD Cowen increased their price objective on shares of AstraZeneca from $90.00 to $95.00 and gave the stock a "buy" rating in a research report on Monday, August 12th. Three analysts have rated the stock with a hold rating, seven have issued a buy rating and two have issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, AstraZeneca presently has a consensus rating of "Moderate Buy" and a consensus target price of $89.75.
Read Our Latest Stock Analysis on AZN
AstraZeneca Stock Up 0.6 %
Shares of AZN traded up $0.42 during mid-day trading on Friday, reaching $67.62. 2,586,327 shares of the stock traded hands, compared to its average volume of 8,232,759. The stock has a fifty day simple moving average of $72.27 and a 200 day simple moving average of $77.43. The firm has a market cap of $209.66 billion, a price-to-earnings ratio of 32.35, a P/E/G ratio of 1.23 and a beta of 0.47. The company has a quick ratio of 0.71, a current ratio of 0.93 and a debt-to-equity ratio of 0.71. AstraZeneca PLC has a 12-month low of $60.47 and a 12-month high of $87.68.
AstraZeneca (NASDAQ:AZN - Get Free Report) last announced its quarterly earnings data on Tuesday, November 12th. The company reported $1.04 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.01 by $0.03. The company had revenue of $13.57 billion for the quarter, compared to analysts' expectations of $13.08 billion. AstraZeneca had a net margin of 12.68% and a return on equity of 30.01%. The business's revenue was up 18.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.87 EPS. Sell-side analysts expect that AstraZeneca PLC will post 4.1 EPS for the current fiscal year.
About AstraZeneca
(
Free Report)
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.
Featured Stories
Before you consider AstraZeneca, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AstraZeneca wasn't on the list.
While AstraZeneca currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
